** Drug developer Alpha Cognition ACOG.O rises 12.5% to $5.91
** ACOG says it has launched its oral therapy, Zunveyl, commercially to treat mild to moderate Alzheimer's disease (AD)
** Alzheimer's is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to do simple tasks, which is the most common form of dementia affecting nearly 7 million people
** Co says patients can now access the drug in 5 milligram (mg), 10 mg and 15 mg doses
** Zunveyl was approved by the FDA to treat AD in July 2024
** Brokerage H.C. Wainwright estimates Zunveyl to generate $540 millon in peak annual sales in the US by the late 2030s
** As of last close, ACOG down ~65% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。